97175 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
METHOD OF INDIRECT IMMUNIZATION OF HUMAN OVARIAN CANCER PATIENTS THROUGH SELECTION OF XENOGENEIC IMMUNOGLOBULIN FC PORTIONS
#2102Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy
#2103IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS
#2104Anti-CD276 antibodies (B7H3)
#2105PDL1-binding proteins
#2106TREATMENT METHOD
#2107Tri-specific binding molecules that specifically bind to multiple cancer antigens
#2108Method treating malignant ascites and metastatic pleural effusion with and disulfide-linked trimeric TRAIL
#2109USE OF ANTI-B7H3 ANTIBODIES FOR TREATING CANCER IN THE CENTRAL NERVOUS SYSTEM
#2110Combination therapy
#2111Treatment of breast cancer using combination therapies comprising an AKT inhibitor, a taxane, and a PD-L1 inhibitor
#2112METHOD OF TREATING CANCER USING IMMUNE CHECKPOINT INHIBITOR
#2113Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)
#2114Antibodies to B7-H1
#2115COMBINATION THERAPY
#2116MULTISPECIFIC ANTIBODY WITH COMBINATION THERAPY FOR IMMUNO-ONCOLOGY
#2117Antibodies against TIM3 and uses thereof
#2118Method for treating cancer using disulfide-linked trimeric 4-1BBL
#2119INTERLEUKIN-2 IMMUNOCONJUGATE, A CD40 AGONIST, AND OPTIONALLY A PD-1 AXIS BINDING ANTAGONIST FOR USE IN METHODS OF TREATING CANCER
#2120Cell engaging binding molecules
#2121BISPECIFIC ANTIBODIES THAT BIND CD 123 CD3
#2122Bispecific antagonist comprising a LAG-3 binding domain
#2123OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapeutic vector, construction method therefor, and use thereof
#2124Malignant glioma CAR-T therapeutic vector based on OCTS technology, and construction method and application thereof
#2125Combination therapies of HDAC inhibitors and PD-L1 inhibitors
#2126Multispecific binding constructs against checkpoint molecules and uses thereof
#2127Scaffold proteins
#2128SPD-1 variant# FC fusion proteins
#2129Method for selecting individuals to be administered immune checkpoint inhibitor
#2130TYPE II ANTI-CD20 ANTIBODY AND ANTI-CD20/CD3 BISPECIFIC ANTIBODY FOR TREATMENT OF CANCER
#2131Recombinant protein targeting PD-L1 and VEGF
#2132Bispecific binding proteins and uses thereof
#2133Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
#2134Dosage regimes for the administration of an anti-CD19 ADC
#2135COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
#2136Nant cancer vaccine
#2137Ceramide nanoliposomes, compositions and methods of using for immunotherapy
#2138STRONG POTENTIATION OF IMMUNE CHECKPOINT BLOCKADE THERAPY OF CANCER BY COMBINATION WITH ENDOGLIN-TARGETING THERAPY
#2139Binding agents binding to PD-L1 and CD137 and use thereof
#2140Bispecific antibodies which bind PD-L1 and GITR
#2141Anti-programmed death-ligand 1 (PD-L1) antibodies and therapeutic uses thereof
#2142Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
#2143METHODS FOR IMPROVING SEX-DIMORPHIC RESPONSES TO TARGETED THERAPY IN MELANOMA
#2144Therapeutic use of inhibitors of t cell activation or stimulation
#2145Crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1-yl)pyrimidin-4-amine and new salts
#2146Use of EZH2 inhibitors for treating cancer
#2147COMPOSITION FOR DELIVERING PHYSIOLOGICALLY ACTIVE INGREDIENTS INTO BLOOD VESSEL
#2148DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER
#2149INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY
#2150MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF
#2151Bispecific recombinant protein and use thereof
#2152Anti-PD-L1 antibodies and uses thereof
#2153Oncolytic viral delivery of therapeutic polypeptides
#2154Tri-specific antibodies
#2155Fusion protein containing TGF-β receptor and medicinal uses thereof
#2156PD-1/PD-L1 inhibitors
#2157METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND IL-17 BINDING ANTAGONISTS
#2158METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTION
#2159Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine
#2160METHODS OF TREATING CANCER USING B-RAF INHIBITORS AND IMMUNE CHECKPOINT INHIBITORS
#2161NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
#2162PD-L1 AND TA-MUC1 ANTIBODIES
#2163Anti-CLL-1 antibodies and methods of use
#2164Anti-PD-L1 nanobody, coding sequence and use thereof
#2165Compositions and methods for tumor vaccination and immunotherapy involving HER antigens
#2166Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the CNS
#2167Anti-PD-L1 antibodies
#2168Reducing systemic regulatory T cell levels or activity for treatment of a retinal degeneration disorder
#2169MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE
#2170METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES
#2171COMBINATION USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR
#2172TIGIT antibodies, encoding nucleic acids and methods of using said antibodies in vivo
#2173Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
#2174COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE
#2175Elimination of PD-L1-positive malignancies by PD-L1 chimeric antigen receptor-expressing NK cells
#2176COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
#2177IDENTIFICATION AND ELIMINATION OF DAMAGED AND/OR SENESCENT CELLS
#2178Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies
#2179Pharmaceutical composition for tumor treatment or prevention, method, and use thereof
#2180COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
#2181Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
#2182Anti-PD-1 antibodies and uses thereof
#2183KRas G12C inhibitors
#2184Methods for treating pancreatic cancer
#2185Methods for reducing side effects of immunotherapy
#2186Therapeutic immunoglobulin G4 for improved bioanalytical and bioprocessing properties
#2187Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
#2188Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
#2189Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
#2190Agents that modulate immune cell activation and methods of use thereof
#2191MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
#2192COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
#2193METHOD OF INDIRECT IMMUNIZATION OF HUMAN OVARIAN CANCER PATIENTS THROUGH SELECTION OF XENOGENEIC IMMUNOGLOBULIN FC PORTIONS
#2194Anti-PD-L1 antibodies
#2195Vista antagonist and methods of use
#2196ANTIGEN BINDING RECEPTOR FORMATS
#2197Treating and preventing microbial infections
#2198Targeted chimeric proteins and uses thereof
#2199ANTIBODIES TARGETING A LIGAND FROM AN IMMUNE CHECKPOINT, WITH AN FC FRAGMENT HAVING AN IMPROVED AFFINITY FOR CD16A
#2200Glucose oxidase-nanoparticle bioconjugates for cancer treatment
#2201Vista modulators for diagnosis and treatment of cancer
#2202T REGULATORY CELLS AND USES THEREOF
#2203Antibodies binding to ILT4
#2204Use of TGF-alpha polypeptide or anti-TGF-alpha antibodies for the treatment of diseases and disorders
#2205B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION
#2206Methods and kits for treating pain
#2207Multispecific molecules and uses thereof
#2208Anti-LAG-3 antibodies and uses thereof
#2209PD-L1 antibody pharmaceutical composition and use thereof
#2210STABILIZED ANTIBODY PROTEIN SOLUTIONS
#2211Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor
#2212COMPOSITION AND PROCESS FOR PREPARING VACCINE
#2213TRISPECIFIC ANTIGEN BINDING PROTEINS
#2214COMBINATION OF AN ANTI-VEGFR-2 ANTIBODY AND AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCER
#2215Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
#2216HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
#2217IMMUNOPOTENTIATIVE COMPOSITION
#2218Targeted TGFβ inhibition
#2219METHOD OF PREDICTING RESPONSE TO IMMUNOTHERAPY
#2220HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR
#2221Anti-B7-H3 antibodies and diagnostic uses thereof
#2222COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER
#2223Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
#2224Tumor treatment method with an individualized peptide vaccine
#2225DOUBLE NEGATIVE T CELLS AND PD-1 BLOCKADE FOR THE TREATMENT OF CANCER
#2226BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS
#2227ANTI-C10ORF54 ANTIBODIES AND USES THEREOF
#2228COMPOSITIONS AND METHODS RELATED TO ENGINEERED FC-ANTIGEN BINDING DOMAIN CONSTRUCTS
#2229Anti-CD112R compositions and methods
#2230Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
#2231Therapeutic and diagnostic methods for cancer
#2232Anti PD-L1 antibodies
#2233B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
#2234COMPOSITION COMPRISING AVELUMAB
#2235Anti-PD-L1 antibody for detecting PD-L1
#2236Anti-ILT3 antibodies and antibody drug conjugates
#2237COMBINATION THERAPIES
#2238High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof
#2239ANTIGEN-SPECIFIC IMMUNE MODULATION
#2240TRISPECIFIC ANTIGEN BINDING PROTEINS
#2241ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES
#2242Isolated B7-H4 specific compositions and methods of use thereof
#2243ANTIBODY-DRUG CONJUGATES WITH IMMUNE-MEDIATED THERAPY AGENTS
#2244Chimeric antigen receptors with BCMA specificity and uses thereof
#2245Compositions and methods targeting complement component 3 for inhibiting tumor growth
#2246Binding molecules that bind CD137 and PD-L1
#2247Anti-vista antibodies and fragments
#2248MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM
#2249B7-DC BINDING ANTIBODY
#2250AQUEOUS ANTI-PD-L1 ANTIBODY FORMULATION
#2251Neoepitope vaccine and immune stimulant combinations and methods
#2252IL-15-based molecules and methods of use thereof
#2253Engineered cells and methods of use
#2254PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
#2255Binding molecules to CD38 and PD-L1
#2256Anti-galectin-9 antibodies and uses thereof
#2257Multifunctional protein molecules comprising decorin and use thereof
#2258METHODS FOR MODULATING AN IMMUNE RESPONSE
#2259USE OF ONCOLYTIC VIRUSES, ALONE OR IN COMBINATION WITH A CHECKPOINT INHIBITOR, FOR THE TREATMENT OF CANCER
#2260NANOPARTICLE FORMULATIONS FOR ENHANCED DRUG DELIVERY TO THE BLADDER
#2261Trispecific antagonists
#2262Antitumor antagonists
#2263ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#2264Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
#2265Antitumor immune checkpoint regulator antagonists
#2266Synthetic library of specific binding molecules
#2267COMBINATION THERAPY BY USING ANTI-GLOBO H OR ANTI-SSEA-4 ANTIBODY WITH ANTI-NEGATIVE IMMUNE CHECK POINTS ANTIBODY
#2268Combination therapy for the treatment of cancer
#2269Monoclonal antibodies targeting epitopes of ASPH
#2270COMPOSITIONS COMPRISING COFORMULATION OF ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES
#2271Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
#2272Methods and compositions for reducing metastases
#2273Coordinated multi-prong cancer therapy
#2274CALRETICULIN-MEDIATED CANCER TREATMENT
#2275METHODS OF TREATING AND PREVENTING MELANOMA WITH S-EQUOL
#2276Methods of treating and preventing breast cancer with S-equol
#2277Compositions containing tucaresol or its analogs
#2278METHOD FOR PREDICTING SENSITIVITY OF CANCER TO TREATMENT WITH PD-1 IMMUNE CHECKPOINT INHIBITOR
#2279COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES
#2280USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS
#2281Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
#2282COMBINATION THERAPY OF TUMOR-TARGETED IL-2 VARIANT IMMUNOCYTOKINES AND ANTIBODIES AGAINST HUMAN PD-L1
#2283Diagnostic and therapeutic methods for cancer
#2284Resistance to checkpoint blockade therapy
#2285Anti-OX40 antibodies and anti-GITR antibodies
#2286Anti-PD-L1 antibody and application thereof
#2287Bispecific signaling agents and uses thereof
#2288Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer
#2289COMBINATION TREATMENTS OF HSP90 INHIBITORS FOR ENHANCING TUMOR IMMUNOGENICITY AND METHODS OF USE THEREOF
#2290TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION
#2291DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES
#2292ANTI-PD-L1 ANTIBODY TREATMENT OF BLADDER CANCER
#2293Anti-SIRPA antibodies and methods of use thereof
#2294Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
#22951-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and use thereof in the treatment of cancer
#2296NOVEL THERAPEUTIC AGENT FOR PRIONOID DISEASES
#2297METHODS FOR MODULATION OF CAR-T CELLS
#2298Method for predicting and monitoring response to an immune checkpoint inhibitor
#2299Antagonizing CD73 antibody
#2300Antibodies against signal-regulatory protein α and methods of use
#2301Clec9A binding agents
#2302Anti-PD-L1 antibody and IL-7 fusions
#2303PD-L1 binding polypeptide or composite
#2304Combinations of cabozantinib and atezolizumab to treat cancer
#2305Antibody binding PD-1 and use thereof
#2306Multivalent antibody
#2307TREATMENT OF CANCERS USING ANTI-EMP2 ANTIBODY AND PD-1/PDL-1 PATHWAY ANTAGONIST COMBINATION THERAPY
#2308Combination Immunotherapy For The Treatment of Cancer
#2309IMMUNE CHECKPOINT THERAPY
#2310PD1-41BBL fusion protein and methods of use thereof
#2311Bridged bicycloalkyl-substituted aminothiazoles and their methods of use
#2312Human kynureninase enzymes and uses thereof
#2313In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors
#2314Anti-B7-H4 antibody
#2315Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
#2316Anti-B7-H1 antibodies for treating tumors
#2317Anti-PD-L1 and IL-2 cytokines
#2318Anti-PD-L1 antibodies
#2319Anti-B7H3 binding compounds and uses thereof
#2320Cell engaging binding molecules
#2321Multi-Specific Molecules
#2322SELECTIVE BCL-2 INHIBITORS IN COMBINATION WITH AN ANTI-PD-1 OR AN ANTI-PD-L1 ANTIBODY FOR THE TREATMENT OF CANCERS
#2323Polypeptide linker for preparing multispecific antibodies
#2324DOSING REGIMENS AND DOSAGE FORMS FOR TARGETED TGF-B INHIBITION
#2325Dosing regimen of avelumab for the treatment of cancer
#2326ANTI-PD-L1 ANTIBODIES
#2327ANTI-PD-L1 MONOCLONAL ANTIBODIES AND FRAGMENTS THEREOF
#2328Anti-human VISTA antibodies and use thereof
#2329Anti-PD-L1 antibodies
#2330Anti-ICOS antibodies
#2331Antibody drug conjugates (ADCs) having enzymatically cleavable groups
#2332INTRATUMORAL VEIN-FORMATION PROMOTING AGENT
#2333HETERODIMERIC ANTIGEN BINDING PROTEINS
#2334TUMOR ANTIGEN SPECIFIC ANTIBODIES AND TLR3 STIMULATION TO ENHANCE THE PERFORMANCE OF CHECKPOINT INTERFERENCE THERAPY OF CANCER
#2335Anti-CD25 antibody agents
#2336Antibody to programmed death-ligand 1 (PD-L1) and use thereof
#2337Anti-PD-1 nano-antibody and application thereof
#2338Treatment of a disease of the gastrointestinal tract with a TLR modulator
#2339IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS
#2340Combination comprising immunostimulatory oligonucleotides
#2341Affinity maturated TAG72 specific single chain antibodies
#2342Methods for treating cancer in patients with elevated levels of Bim
#2343Therapeutic and diagnostic methods for cancer
#2344Anti-TIGIT antibodies
#2345Humanized and affinity matured antibodies to FcRH5 and methods of use
#2346RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY
#2347Cell engaging binding molecules
#2348Cell engaging binding molecules
#2349Treatment of tumors with an anti-CSF-1R antibody in combination with an anti-PD-L1 antibody after failure of anti-PD-L1/PD1 treatment
#2350METHODS OF TREATING CANCER USING ANTI-PD-L1 ANTIBODIES AND ANTIANDROGENS
#2351METHODS AND COMPOSITIONS RELATED TO NK CELL AND ANTI-PDL1 CANCER THERAPIES
#2352Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
#2353Use of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) agonists to improve ex vivo expansion of tumor infiltrating lymphocytes (TILS)
#2354Anti-CD25 antibody agents
#2355VISTA ANTIGEN-BINDING MOLECULES
#2356Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
#2357Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof
#2358METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON SMALL CELL LUNG CANCER (NSCLC) THAT COEXISTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
#2359Use of Antibody Drug Conjugates Comprising Tubulin Disrupting Agents to Treat Solid Tumor
#2360COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF OVARIAN CANCER
#2361PDL1 block CAR-T transgenic vector for suppressing immune escape, preparation method thereof, and application of the same
#2362Methods and Systems for Predicting Response to Immunotherapies for Treatment of Cancer
#2363Heterodimeric immunoglobulin constructs and preparation methods thereof
#2364Anti-CD25 antibody agents
#2365Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R)
#2366ANTIBODIES DIRECTED AGAINST T CELL IMMUNOGLOBULIN AND MUCIN PROTEIN 3 (TIM-3)
#2367Methods for treatment of cancer comprising TIGIT-binding agents
#2368Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof
#2369TAG-72-binding chimeric antigen receptors
#2370Anti-CD46 antibodies and methods of use
#2371COMPOSITIONS AND METHODS FOR TREATING LATE STAGE LUNG CANCER
#2372HUMAN ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
#2373Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#2374Methods and compositions for inducing an immune response
#2375FLUOROCYCLOPENTENYLCYTOSINE METHODS OF USE
#2376COMBINATION THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR
#2377Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
#2378Anti-PD-1 antibodies
#2379TREATING CANCER WITH A COMBINATION OF A PD-1 ANTAGONIST AND AN IL-27 ANTAGONIST
#2380PD-1/PD-L1 inhibitors
#2381GLA monotherapy for use in cancer treatment
#2382COMBINATION THERAPY WITH MERESTINIB AND ANTI-PD-L1 OR ANTI-PD-1 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
#2383METHODS OF TREATING SOLID TUMORS WITH CCR2 ANTAGONISTS
#2384Multivalent and multispecific OX40-binding fusion proteins
#2385Antibody binding specifically to CD66c and use thereof
#2386CD3 binding antibodies
#2387Recombinant antibody and uses thereof
#2388CD80 and CD86 binding protein compositions and uses thereof
#2389IL-15 variants and uses thereof
#2390ARTIFICIAL ANTIGEN PRESENTING CELLS FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY
#2391Anti-galectin-9 antibodies and uses thereof
#2392ANTI-PD-L1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL CELL LUNG CANCER
#2393Binding molecules binding PD-L1 and LAG-3
#2394Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof
#2395Apparatus and method for the treatment of melanoma
#2396Chemically-locked bispecific antibodies
#2397Antibody to programmed cell death 1 (PD-1) and use thereof
#2398ANTIBODIES AGAINST TIM3 AND USES THEREOF
#2399BSL2v2c2-Ig polypeptides
#2400Anti-PD-L1-anti-TIM-3 bispecific antibodies